MARKSANS.NS Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 12:00):

Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, distribution, and sale of generic pharmaceutical formulations worldwide...

Stats
Tagesvolumen	2.11M
Durchschnittsvolumen	1.87M
Marktkapitalisierung	78.01B
EPS	INR0 ( 2024-02-14 )
Nächstes Ertragsdatum	( INR0 ) 2024-05-27
Last Dividend	INR0.500 ( 2023-06-07 )
Next Dividend	INR0 ( N/A )
P/E	24.42
ATR14	INR0.256 (0.15%)

Volumen Korrelation

Lang: 0.07 (neutral)

Kurz: -0.23 (neutral)

Signal:(39.297) Neutral

Marksans Pharma Limited Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Marksans Pharma Limited Korrelation - Währung/Rohstoff

0.02
( neutral )

-0.12
( neutral )

0.00
( neutral )

0.21
( neutral )

0.10
( neutral )

-0.43
( neutral )

Marksans Pharma Limited Finanzdaten

Annual	2022
Umsatz:	INR18.52B
Bruttogewinn:	INR9.31B (50.25 %)
EPS:	INR6.41

FY	2022
Umsatz:	INR18.52B
Bruttogewinn:	INR9.31B (50.25 %)
EPS:	INR6.41

FY	2022
Umsatz:	INR14.80B
Bruttogewinn:	INR7.32B (49.46 %)
EPS:	INR4.56

FY	2021
Umsatz:	INR13.68B
Bruttogewinn:	INR7.50B (54.79 %)
EPS:	INR5.83

Financial Reports:

No articles found.

Marksans Pharma Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0.250 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0.500 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Marksans Pharma Limited Dividend Information - Dividend Junior

Dividend Sustainability Score: 4.54 - low (50.90%) | Divividend Growth Potential Score: 5.08 - Stable (1.65%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR0.100	2014-09-18
Last Dividend	INR0.500	2023-06-07
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	10	--
Total Paid Out	INR1.590	--
Avg. Dividend % Per Year	0.40%	--
Score	2.2	--
Div. Sustainability Score	4.54
Div.Growth Potential Score	5.08
Div. Directional Score	4.81	--

Next Divdend (Est)
(2025-03-25)

INR0.618 Estimate 3.11 %

Dividend Stability

0.25 Very Poor

Dividend Score

2.20

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR0.0500	0.16%
2019	INR0.0500	0.18%
2020	INR0.100	0.58%
2021	INR0.250	0.41%
2022	INR0.250	0.41%
2023	INR0.500	0.85%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
RITES.NS	Dividend Knight	2023-09-08	Quarterly	7	3.95%
LAMBODHARA.NS	Dividend Junior	2023-09-14	Annually	10	0.87%
FORCEMOT.NS	Dividend Junior	2023-09-21	Annually	6	0.45%
APLAPOLLO.NS	Ex Dividend Junior	2023-09-01	Sporadic	13	0.07%
TATVA.NS	Dividend Junior	2023-09-08	Annually	3	0.04%
NUCLEUS.NS	Dividend Junior	2023-07-07	Annually	22	1.41%
INDUSINDBK.NS	Dividend Junior	2023-06-02	Annually	23	0.56%
COLPAL.NS	Dividend Knight	2023-05-19	Semi-Annually	18	1.38%
SBIN.NS	Dividend Junior	2023-05-31	Sporadic	29	0.99%
MAHSEAMLES.NS	Dividend Junior	2023-08-14	Annually	21	0.80%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.151	1.500	6.98	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.174	1.500	9.17	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	48.41	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	2.96	2.00	9.01	10.00	[0 - 30]
freeCashFlowPerShareTTM	2.96	2.00	8.52	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.519	1.000	4.69	4.69	[0.2 - 0.8]
operatingProfitMarginTTM	0.203	1.000	7.95	7.95	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.54

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	24.58	1.000	7.62	0	[1 - 100]
returnOnEquityTTM	0.174	2.50	9.47	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	2.96	2.00	9.01	10.00	[0 - 30]
dividendYielPercentageTTM	0.290	1.500	2.74	0	[0 - 0.4]
operatingCashFlowPerShareTTM	2.96	2.00	9.01	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.878	1.500	7.48	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0639	1.000	-0.904	0	[0.1 - 0.5]
Total Score				5.08

Marksans Pharma Limited

Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, distribution, and sale of generic pharmaceutical formulations worldwide. The company offers products in the analgesics, benign prostatic hyperplasia, antidiabetic, epilepsy, anti-inflammatory, hyperparathyroidism, diabetes, antacids, neurology, cardiovascular, hormonal, oncology, gastroenterology, antidiabetic, pain management, gynecology, antibiotic, antifungal, antiulceratives, vitamins, dermatology, cephalosporins, injectables, anti-allergy, antibacterial, and hypertension therapeutic areas. It also provides contract research and manufacturing services. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.